TGTX News & Events

TG Therapeutics announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating Briumvi in people with highly active relapsing forms of multiple sclerosis. The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Dusseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as greater than or equal to 2 relapses in the year prior and greater than or equal to 1 gadolinium-enhancing T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity, with Briumvi compared to teriflunomide.

Precision BioSciences (DTIL) announced the achievement of a clinical milestone under its license agreement with TG Therapeutics (TGTX). The milestone payment for azercabtagene zapreleucel was triggered by progress of a Phase 1 clinical trial of azer-cel in progressive forms of multiple sclerosis. As a result of this milestone event, Precision will receive $7.5M in proceeds, inclusive of $5.25M cash and $2.25M for the purchase of 201,504 shares of Precision common stock by TG Therapeutics at $11.17 per share, pursuant to the terms of the companies' license agreement. Existing cash and cash equivalents, inclusive of the azer-cel milestone proceeds, continued fiscal and operating discipline, and availability of the ATM facility, are expected to provide sufficient cash runway through 2028. In January 2024, Precision BioSciences announced a licensing deal, granting TG Therapeutics exclusive worldwide rights to develop and commercialize azer-cel in autoimmune diseases and other non-oncology indications. Under the agreement, Precision received upfront and potential near-term economics and remains eligible for additional development, regulatory, and commercial milestone payments, as well as royalties on net sales. Precision is eligible to receive up to $288M in additional milestone payments as well as high-single-digit to low-double-digit royalties on net sales.

Cash, cash equivalents and investment securities were $199.5 million as of December 31, 2025. We anticipate that our cash, cash equivalents and investment securities as of December 31, 2025, combined with the projected revenues from BRIUMVI, will be sufficient to fund our business based on our current operating plan.

Reports Q4 revenue $192.6M, consensus $193.34M. Michael Weiss, CEO, stated, "2025 was a strong year of execution for TG Therapeutics, driven by continued momentum for BRIUMVI and meaningful progress across our organization. BRIUMVI delivered significant year-over-year growth in the U.S., supported by increasing adoption and expanding global availability, while we advanced multiple late-stage clinical programs and strengthened our financial position. As we enter 2026, we are focused on building on this foundation. With strong financial guidance, several important clinical milestones ahead, and a disciplined approach to operations, we believe we are well positioned to continue delivering value for patients, healthcare providers, and shareholders."